Search

Displaying results 2391 - 2400 of 10000 in total
  1. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

    Mixtures: A-FERIN SINUS 500/30/1.25 MG FİLM KAPLI TABLET, 20 ADET, TRIFEN 100 ML SUS.Products: M-Hist PD
  2. Drug

    Semduramicin

    go.drugbank.com/drugs/DB11545
    ExperimentalVet approved

    Products: Semduramicin 150
  3. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune … Since June 2016, Velpatasvir has been available as a fixed dose combination product with [DB08934], as the commercially available product Epclusa.

    Mixtures: VOSEVİ 400 MG/ 100 MG/ 100 MG FİLM KAPLI TABLET, 28 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Molybdenum

    go.drugbank.com/drugs/DB11137
    ApprovedInvestigational

    Molybdenum is a chemical element with symbol Mo and atomic number 42. As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation states in minerals. … When complexed with Technetium Tc 99m, molybdenum is used as a radiopharmaceutical agent in diagonistic procedures.

    Mixtures: Men's 50+, Adult Formula 50+
  5. Drug

    Befovacimab

    go.drugbank.com/drugs/DB16188
    Investigational

    Synonyms: Human tissue factor pathway inhibitor-neutralizing antibody (bay 1093884)
  6. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  7. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week. … [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327]

  8. Drug

    Coagulation factor VII human

    go.drugbank.com/drugs/DB13150
    ApprovedInvestigational

    Coagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETProducts: Faktor VII "Takeda" 600 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
  9. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890].

  10. Drug

    Rimantadine

    go.drugbank.com/drugs/DB00478
    Approved

    An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.

    Categories: M2 Protein Inhibitors, Influenza A M2 Protein Inhibitor